Dapagliflozin-Induced Myocardial Flow Reserve Improvement is not Associated with HDL Ability to Stimulate Endothelial Nitric Oxide Production

ConclusionsIn patients with T2D-CAD, beneficial effects of dapagliflozin on coronary microcirculation seem to be unrelated to HDL functions. However, HDL capacity to stimulate NO production is not impaired at baseline; thus, the effect of drug treatments would be negligible. To conclude, we can assume that HDL-independent molecular pathways are involved in the improvement of MFR in this population.Trial RegistrationEudraCT No. 2016-003614-27; ClinicalTrials.gov Identifier: NCT03313752.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research